Empfehlung
10,3
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Score-Verlauf (90 Tage)
Stammdaten
Unternehmen
| Name | AGIOS PHARMACEUTICALS, INC. |
|---|---|
| Ticker | AGIO |
| CIK | 0001439222 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | AGIOS PHARMACEUTICALS, INC. |
Status
| Zuletzt geprüft | 2026-03-20 22:35:55.748732 |
|---|
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 54,028,000 | -412,781,000 | -7.12 | 1,297,225,000 | 1,193,114,000 |
| 2018-12-31 | 10-K | 30,013,000 |
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | Viswanadhan Krishnan | Officer, Chief Corp Dev & Strategy | Open Market Sale | -2,959 | 27.80 | -82,260.20 | -81,0% | |
| 2026-03-05 | Viswanadhan Krishnan | Officer, Chief Corp Dev & Strategy | Open Market Sale | -2,959 | 27.80 | -82,260.20 | -81,0% | |
| 2026-03-03 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -5,272 | 28.88 | -152,255.36 | -150,0% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -727 | 28.96 | -21,053.92 | -20,7% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -798 | 28.96 | -23,110.08 | -22,8% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -3,870 | 28.96 | -112,075.20 | -110,4% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -8,267 | 28.96 | -239,412.32 | -235,8% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -5,918 | 28.96 | -171,385.28 | -168,8% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1,187 | 28.96 | -34,375.52 | -33,9% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1,681 | 28.96 | -48,681.76 | -48,0% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1,163 | 28.96 | -33,680.48 | -33,2% | |
| 2026-03-02 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -1,187 | 28.96 | -34,375.52 | -33,9% | |
| 2026-03-02 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -1,681 | 28.96 | -48,681.76 | -48,0% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -594 | 28.96 | -17,202.24 | -16,9% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1,681 | 28.96 | -48,681.76 | -48,0% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1,187 | 28.96 | -34,375.52 | -33,9% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1,573 | 28.96 | -45,554.08 | -44,9% | |
| 2026-03-02 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -1,681 | 28.96 | -48,681.76 | -48,0% | |
| 2026-03-02 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -1,187 | 28.96 | -34,375.52 | -33,9% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -698 | 28.96 | -20,214.08 | -19,9% | |
| 2026-01-05 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2,872 | 27.02 | -77,601.44 | -76,4% | |
| 2025-12-30 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2,932 | 27.09 | -79,427.88 | -78,2% | |
| 2025-12-30 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -2,932 | 27.09 | -79,427.88 | -78,2% | |
| 2025-12-30 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -12,473 | 27.09 | -337,893.57 | -332,9% | |
| 2025-12-30 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -6,230 | 27.09 | -168,770.70 | -166,3% | |
| 2025-12-30 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2,932 | 27.09 | -79,427.88 | -78,2% | |
| 2025-12-30 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -2,932 | 27.09 | -79,427.88 | -78,2% | |
| 2025-11-12 | Scadden David | Director | Open Market Sale | -200 | 43.84 | -8,768.00 | -8,6% | |
| 2025-11-12 | Scadden David | Director | Open Market Sale | -200 | 43.84 | -8,768.00 | -8,6% | |
| 2025-11-11 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2,454 | 43.78 | -107,436.12 | -105,8% | |
| 2025-10-30 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -200 | 43.81 | -8,762.00 | -8,6% | |
| 2025-10-27 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -3,302 | 43.92 | -145,023.84 | -142,9% | |
| 2025-10-08 | Scadden David | Director | Open Market Sale | -200 | 41.00 | -8,200.00 | -8,1% | |
| 2025-10-08 | Scadden David | Director | Open Market Sale | -200 | 41.00 | -8,200.00 | -8,1% | |
| 2025-09-30 | Scadden David | Director | Open Market Sale | -200 | 40.00 | -8,000.00 | -7,9% | |
| 2025-09-30 | Scadden David | Director | Open Market Sale | -200 | 40.00 | -8,000.00 | -7,9% | |
| 2025-09-26 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -3,651 | 36.77 | -134,247.27 | -132,2% | |
| 2025-09-05 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -8,546 | 36.87 | -315,091.02 | -310,4% | |
| 2025-08-27 | Scadden David | Director | Open Market Sale | -200 | 40.00 | -8,000.00 | -7,9% | |
| 2025-08-27 | Scadden David | Director | Open Market Sale | -200 | 40.00 | -8,000.00 | -7,9% | |
| 2025-08-08 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -11,085 | 36.67 | -406,486.95 | -400,4% | |
| 2025-07-10 | Scadden David | Director | Open Market Sale | -1,400 | 40.00 | -56,000.00 | -55,2% | |
| 2025-07-10 | Scadden David | Director | Open Market Sale | -1,400 | 40.00 | -56,000.00 | -55,2% | |
| 2025-07-09 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -847 | 38.76 | -32,829.72 | -32,3% | |
| 2025-07-09 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -11,067 | 37.93 | -419,771.31 | -413,5% | |
| 2025-07-01 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -4,091 | 34.17 | -139,789.47 | -137,7% | |
| 2025-06-24 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1,780 | 33.54 | -59,701.20 | -58,8% | |
| 2025-06-24 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -2,799 | 33.54 | -93,878.46 | -92,5% | |
| 2025-06-24 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2,909 | 33.54 | -97,567.86 | -96,1% | |
| 2025-06-24 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2,770 | 33.54 | -92,905.80 | -91,5% | |
| 2025-06-24 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -12,471 | 33.54 | -418,277.34 | -412,0% | |
| 2025-06-24 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -6,229 | 33.54 | -208,920.66 | -205,8% | |
| 2025-04-10 | FOUSE JACQUALYN A | Director | Open Market Sale | -7,497 | 25.90 | -194,172.30 | -191,3% | |
| 2025-04-10 | FOUSE JACQUALYN A | Director | Open Market Sale | -7,497 | 25.90 | -194,172.30 | -191,3% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.